Trodelvy (sacituzumab govitecan) led to a 51% reduction in the risk of progression or death compared with chemotherapy in patients with nonsquamous epidermal growth factor receptor–mutated non–small cell lung cancer that developed epidermal…
Category: 6. Business
-
Amazon (AMZN) Stock in Focus as BofA Names It Top Large-Cap E-Commerce Pick
Amazon.com, Inc. (NASDAQ:AMZN) is one of the AI Stocks in the Spotlight This Week. On October 17, Bank of America reiterated Amazon and Chewy as “Buy,” stating that both stocks are top ideas in e-commerce.
“Amazon remains our top…
Continue Reading
-
Sirexatamab Plus Bevacizumab/Chemo Improves Outcomes in DKK1-High mCRC
Sirexatamab (DKN-01) in combination with bevacizumab (Avastin) and standard-of-care (SOC) chemotherapy demonstrated a manageable safety profile and was well tolerated vs bevacizumab plus SOC chemotherapy in patients with metastatic colorectal…
Continue Reading
-
India’s Largest Silver Refinery Runs Out of Silver
India’s Largest Silver Refinery Runs Out of Silver | The Jerusalem PostJerusalem Post/Business & Innovation/Precious MetalsIndia’s largest silver refinery has run out of silver for the first time ever, exposing a global shortage and sending…
Continue Reading
-
Tislelizumab Plus Chemo/Concurrent Chemoradiotherapy Yields Survival Advantage in Locally Advanced ESCC
The addition of tislelizumab-jsgr (Tevimbra) to induction chemotherapy and concurrent chemoradiotherapy (CRT) boasted higher composite complete response (cCR) rates, which translated to improved survival vs the historical control of concurrent…
Continue Reading
-
Zipalertinib Shows Early Efficacy With Manageable Safety in EGFR-Mutant NSCLC With CNS or Leptomeningeal Disease
The intracranial objective response rate (ORR) in RANO-BM–evaluable patients (n = 16) was 31.3% (n = 5), which included 1 intracranial complete response. Notably, 2 of 5 intracranial responders also had leptomeningeal disease at baseline, and…
Continue Reading
-
ESMO 2025: CELC-G-201: Phase 1/2 Study of Gedatolisib in Combination with Darolutamide in mCRPC – UroToday
- ESMO 2025: CELC-G-201: Phase 1/2 Study of Gedatolisib in Combination with Darolutamide in mCRPC UroToday
- Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic…
Continue Reading
-
Durvalumab Plus Chemo Yields Inconclusive Results in Advanced Pleural Mesothelioma
Durvalumab (Imfinzi) in combination with chemotherapy produced outcomes consistent with prior studies in patients with advanced pleural mesothelioma, demonstrating favorable overall survival (OS), progression-free survival (PFS), and objective…
Continue Reading
-
An Inflation Update in a Data Desert. Plus, Tesla, Coca-Cola, Netflix, T-Mobile, and Many More Stocks to Watch This Week. – Barron's
- An Inflation Update in a Data Desert. Plus, Tesla, Coca-Cola, Netflix, T-Mobile, and Many More Stocks to Watch This Week. Barron’s
- Tesla, Netflix set to report earnings as US-China trade fight turns ‘unsustainable’: What to watch this week Yahoo…
Continue Reading
-
Durvalumab/Chemotherapy Prove Inconclusive in Phase 3 for Mesothelioma | Targeted Oncology
In the phase 3 DREAM3R trial (NCT04334759, ACTRN12620001199909), first-line durvalumab (Imfinzi) plus chemotherapy demonstrated consistent overall survival (OS), progression-free survival (PFS), and objective response rates (ORR)benefits in…
Continue Reading